Collaboration with CardioNXT provides navigation and mapping system integration with Pulse Biosciences’ nsPFA circumferential catheter to support first-in-human treatments
.
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation, today announced nsPFA will be featured. | May 18, 2023
Same-day discharge did not raise risk for readmission in patients with atrial fibrillation who underwent left atrial appendage closure without complications, researchers reported. The researchers conducted a retrospective cohort study of 48,953 patients (mean age, 76 years; 40% women) with AF who underwent percutaneous left atrial appendage (LAA) closure for stroke prevention from 2015 to